KLA Corp. vs NeoGenomics Inc. Common Stock — how do they compare? KLA Corp. trades at $175.21 (market cap $233.35B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B). The key difference: KLA Corp. is far larger — about 107.5× NeoGenomics Inc. Common Stock's market cap, and KLA Corp. pays a 0.51% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| KLAC | NEO | |
|---|---|---|
Market Cap | $233.35B | $2.17B |
Volume | 14,457,699 | 1,615,943 |
Sector | Technology | Health |
52-Week High | $301.71 | $19.91 |
52-Week Low | $108.70 | $7.19 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $234.60B | $2.47B |
Dividend Yield | 0.51% | — |
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $184.00, down 3.22% on the day, with strong fundamental performance including 35.57% net income margin and 87.5% ROE. The stock shows bullish technical signals with recent earnings beats and a $12.57 billion backlog driven by AI demand. Revenue grew to $12.16 billion in 2025, with analysts projecting $13.6 billion for 2026.
Outlook remains positive with 63.6% analyst buy ratings and $223.88 consensus price target, representing 22% upside. Key risks include competitive pressures from AMAT and ASML, margin compression, and cyclical semiconductor equipment spending. The company's dominant position in semiconductor inspection equipment supports long-term growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →